TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (ACTION-001)
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates reaching 50% and 70%, respectively. Currently, no standard perioperative treatment is recommended in domestic and international guidelines.
Recently, data from a phase III clinical study, investigating neoadjuvant and adjuvant therapy with camrelizumab plus apatinib in resectable HCC patients at intermediate-to-high risk of recurrence, demonstrated that the neoadjuvant and adjuvant therapy combining targeted therapy and immunotherapy could significantly reduce postoperative recurrence. The median recurrence-free survival (RFS) in the target-immunotherapy group was 42.1 months, which was remarkably longer than 19.4 months in the surgery-alone group.
Local therapies (TACE, ablation) can induce immunogenic cell death of tumors and remodel the tumor microenvironment, thereby exerting synergistic effects with immunotherapy. This strategy is expected to further improve recurrence-free survival in HCC patients after surgery.
This clinical trial aims to explore the efficacy and tolerability of the following regimens compared with surgery alone:
- TACE or ablation combined with anti-CTLA-4 and anti-PD-1 immunotherapy;
- TACE or ablation combined with anti-CTLA-4 + anti-PD-1 + lenvatinib;
- Dual immunotherapy with anti-CTLA-4 and anti-PD-1;
- Anti-CTLA-4 + anti-PD-1 + lenvatinib. Efficacy differences between groups will be compared using Bayesian statistical methods based on non-informative priors.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
-
1) Age: 18-75 years old; 2) Patients with hepatocellular carcinoma (HCC) classified as CNLC stage Ib-IIIa (excluding patients with Vp3 and Vp4), and deemed resectable by multidisciplinary team (MDT) discussion;
3) No prior tumor-related treatment received;
4) At least one measurable target lesion according to the RECIST 1.1 criteria;
5) ECOG PS score of 0-1;
6) Liver function classification: Child-Pugh Class A;
7) Estimated survival time ≥ 12 weeks;
8) Hematological, liver, and renal functions meet the following criteria:
-
Hemoglobin concentration ≥ 90 g/L;
-
Neutrophil count ≥ 1.5 × 10⁹/L;
-
Platelet count ≥ 75 × 10⁹/L;
-
Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal);
-
AST and ALT < 5 × ULN; ALP < 4 × ULN;
-
Creatinine ≤ 1.5 × ULN;
-
INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN;
-
Serum albumin concentration ≥ 30 g/L;
9) Women of childbearing age must be excluded from pregnancy;
10) For patients with other concurrent malignant tumors, MDT discussion must confirm that the history and treatment history of other tumors will not interfere with the efficacy and safety evaluation of this study protocol;
11) Ability to understand and sign the informed consent form.
Exclusion Criteria:
-
-
1) Prior history of HCC treatment; 2) Tumor rupture and bleeding, or suspected peritoneal metastasis;
3) History of other complex surgeries within 6 weeks;
4) Prior history of organ transplantation;
Currently receiving treatment in other clinical trials;
5) Prior history of autoimmune diseases, inflammatory disorders (such as inflammatory bowel disease, etc.), diverticulitis, systemic lupus erythematosus, sarcoidosis syndrome, Wegener's syndrome (granulomatosis with polyangiitis, rheumatoid arthritis, etc.), except for the following cases: vitiligo or alopecia areata, hypothyroidism with stable condition after drug replacement therapy, chronic skin diseases that do not require systemic treatment, and celiac disease controllable by diet alone;
6) Prior history of allergy to anti-PD1 drugs or anti-CTLA4 drugs, or allergy to chemical molecules similar to the above drugs, or prior severe allergic reaction to other monoclonal antibodies;
7) Uncontrollable intermittent recurrent diseases, including but not limited to: persistent infections (including tuberculosis), hypertension uncontrollable by drugs (> 140/90 mmHg), interstitial lung disease, severe chronic gastrointestinal diseases complicated with diarrhea, mental illness or social disorders that cannot comply with clinical research requirements, factors with high risk of side effects, and inability to sign the informed consent form;
8) Patients with prior hepatic encephalopathy, refractory ascites, or esophagogastric varices with high bleeding risk; patients with upper gastrointestinal bleeding within 1 year before the first administration;
9) Untreated active hepatitis B subjects (HBsAg positive and HBV-DNA exceeding 5000 copies/mL (1000 IU/mL) or higher than the lower limit of detection, whichever is higher); for subjects with hepatitis B, anti-hepatitis B virus treatment is required during the study treatment; active hepatitis C subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection);
10) Patients with primary brain tumors (except meningiomas or other benign brain tumors), or any brain metastases, leptomeningeal carcinomatosis, epilepsy uncontrollable by conventional drugs, or new-onset stroke within 1 year;
11) Primary immunodeficiency disease;
12) Prior positive HIV test or acquired immunodeficiency syndrome (AIDS);
13) Use of immunosuppressive drugs within 14 days before the start of study treatment. The following situations are exempt:
-
Intranasal, inhaled, topically used steroids or local steroid injections;
-
Systemic application of corticosteroids not exceeding the physiological dose (e.g., 10 mg/day prednisone or its equivalent);
-
Steroid application for the treatment of allergic reactions;
14) Vaccination with live-attenuated vaccines within 30 days before the start of study treatment. Note: Live-attenuated vaccines should also be avoided during the study treatment and within 30 days after the end of treatment;
15) Receipt of systemic immunostimulant treatment within the prior 4 weeks;
16) Prior history of severe systemic diseases, including: myocardial infarction or unstable angina pectoris, hypertensive crisis or hypertensive encephalopathy, congestive heart failure of NYHA Class II or above, unstable symptomatic arrhythmia requiring drug intervention, severe vascular disease or symptomatic peripheral vascular disease, occurring within 12 months before the start of study treatment;
17) History of coagulative, hemorrhagic or thrombotic diseases within 12 months before the start of study treatment;
18) Severe, irreversible trauma, ulcers or fractures;
19) Pregnant or lactating women, or subjects planning to have children during the trial period;
20) Dependent on parenteral nutrition to maintain life;
21) Other acute or chronic diseases, mental and psychological diseases, etc., which are not suitable for participating in this study, as judged by the researcher.
Trial design
Primary purpose
Allocation
Interventional model
Masking
105 participants in 5 patient groups
Trial contacts and locations
Loading...
Central trial contact
Ming Ming
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal